Leucine-rich repeat kinase 2 biomarkers for Parkinson's disease

被引：0

作者：

Dzamko, Nicolas ^{[1
]}

机构：

[1] Univ Sydney, Fac Med & Hlth, Brain & Mind Ctr, Camperdown, NSW, Australia

来源：

BIOCHEMICAL JOURNAL | 2025年 / 482卷 / 11期

关键词：

MITOCHONDRIAL-DNA DAMAGE; RAB10; PHOSPHORYLATION; ALPHA-SYNUCLEIN; LRRK2; MUTATIONS; BIS(MONOACYLGLYCEROL)PHOSPHATE; EXOSOMES; MONITOR; CELLS; GENE;

D O I：

10.1042/bcj20253099

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Leucine-rich repeat kinase 2 (LRRK2) has emerged as a promising therapeutic target for the treatment of neurodegenerative Parkinson's disease (PD). Data from a multitude of pre-clinical models are supportive of a potential role for LRRK2 therapies to ameliorate cellular dysfunctions found in PD, and small molecules to inhibit LRRK2 kinase activity, as well as antisense oligonucleotides to target the protein itself, are in clinical trials. Despite this, exactly how LRRK2 contributes to PD pathogenesis remains to be determined, and definitive biomarkers to track LRRK2 function are still required. Such biomarkers can be useful for monitoring the pharmacodynamic response of LRRK2 therapeutics and/or understanding the relationship between LRRK2 and the clinical progression of PD. Moreover, biomarkers that can identify increased LRRK2 levels or activity beyond just carriers of pathogenic LRRK2 mutations will be important for expanding LRRK2 therapeutics to other PD populations. This review summarizes recent findings regarding biomarkers of LRRK2.

引用

页码：711 / 722

页数：12

共 98 条

[11] Measurement of LRRK2 and Ser910/935 Phosphorylated LRRK2 in Peripheral Blood Mononuclear Cells from Idiopathic Parkinson's Disease Patients [J].

Dzamko, Nicolas ;

Chua, Germaine ;

Ranola, Madelaine ;

Rowe, Dominic B. ;

Halliday, Glenda M. .

JOURNAL OF PARKINSONS DISEASE, 2013, 3 (02) :145-152

[12] The IkappaB Kinase Family Phosphorylates the Parkinson's Disease Kinase LRRK2 at Ser935 and Ser910 during Toll-Like Receptor Signaling [J].

Dzamko, Nicolas ;

Inesta-Vaquera, Francisco ;

Zhang, Jiazhen ;

Xie, Chengsong ;

Cai, Huaibin ;

Arthur, Simon ;

Tan, Li ;

Choi, Hwanguen ;

Gray, Nathanael ;

Cohen, Philip ;

Pedrioli, Patrick ;

Clark, Kristopher ;

Alessi, Dario R. .

PLOS ONE, 2012, 7 (06)

[13] LRRK2 and its substrate Rab GTPases are sequentially targeted onto stressed lysosomes and maintain their homeostasis [J].

Eguchi, Tomoya ;

Kuwahara, Tomoki ;

Sakurai, Maria ;

Komori, Tadayuki ;

Fujimoto, Tetta ;

Ito, Genta ;

Yoshimura, Shin-ichiro ;

Harada, Akihiro ;

Fukuda, Mitsunori ;

Koike, Masato ;

Iwatsubo, Takeshi .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2018, 115 (39) :E9115-E9124

[14] Interrogating Parkinson's disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophils [J].

Fan, Ying ;

Howden, Andrew J. M. ;

Sarhan, Adil R. ;

Lis, Pawel ;

Ito, Genta ;

Martinez, Terina N. ;

Brockmann, Kathrin ;

Gasser, Thomas ;

Alessi, Dario R. ;

Sammler, Esther M. .

BIOCHEMICAL JOURNAL, 2018, 475 :23-44

[15] Pathogenic LRRK2 regulates centrosome cohesion via Rab10/RILPL1-mediated CDK5RAP2 displacement [J].

Fdez, Elena ;

Madero-Perez, Jesus ;

Lara Ordonez, Antonio J. ;

Naaldijk, Yahaira ;

Fasiczka, Rachel ;

Aiastui, Ana ;

Ruiz-Martinez, Javier ;

Lopez de Munain, Adolfo ;

Cowley, Sally A. ;

Wade-Martins, Richard ;

Hilfiker, Sabine .

ISCIENCE, 2022, 25 (06)

[16] MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibitions [J].

Fell, Matthew J. ;

Mirescu, Christian ;

Basu, Kallol ;

Cheewatrakoolpong, Boonlert ;

DeMong, Duane E. ;

Ellis, J. Michael ;

Hyde, Lynn A. ;

Lin, Yinghui ;

Markgraf, Carrie G. ;

Mei, Hong ;

Miller, Michael ;

Poulet, Frederique M. ;

Scott, Jack D. ;

Smith, Michelle D. ;

Yin, Zhizhang ;

Zhou, Xiaoping ;

Parker, Eric M. ;

Kennedy, Matthew E. ;

Morrow, John A. .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2015, 355 (03) :397-409

[17] Centrosomal cohesion deficits as cellular biomarker in lymphoblastoid cell lines from LRRK2 Parkinson's disease patients [J].

Fernandez, Belen ;

Lara Ordonez, Antonio Jesus ;

Fdez, Elena ;

Mutez, Eugenie ;

Comptdaer, Thomas ;

Leghay, Coline ;

Kreisler, Alexandre ;

Simonin, Clemence ;

Vandewynckel, Laurine ;

Defebvre, Luc ;

Destee, Alain ;

Bleuse, Severine ;

Taymans, Jean-Marc ;

Chartier-Harlin, Marie-Christine ;

Hilfiker, Sabine .

BIOCHEMICAL JOURNAL, 2019, 476 :2797-2813

[18] Ser(P)-1292 LRRK2 in urinary exosomes is elevated in idiopathic Parkinson's disease [J].

Fraser, Kyle B. ;

Rawlins, Ashlee B. ;

Clark, Rachel G. ;

Alcalay, Roy N. ;

Standaert, David G. ;

Liu, Nianjun ;

West, Andrew B. .

MOVEMENT DISORDERS, 2016, 31 (10) :1543-1550

[19] Urinary LRRK2 phosphorylation predicts parkinsonian phenotypes in G2019S LRRK2 carriers [J].

Fraser, Kyle B. ;

Moehle, Mark S. ;

Alcalay, Roy N. ;

West, Andrew B. .

NEUROLOGY, 2016, 86 (11) :994-999

[20] LRRK2 secretion in exosomes is regulated by 14-3-3 [J].

Fraser, Kyle B. ;

Moehle, Mark S. ;

Daher, Joao P. L. ;

Webber, Philip J. ;

Williams, Jeri Y. ;

Stewart, Carrie A. ;

Yacoubian, Talene A. ;

Cowell, Rita M. ;

Dokland, Terje ;

Ye, Tong ;

Chen, Dongquan ;

Siegal, Gene P. ;

Galemmo, Robert A. ;

Tsika, Elpida ;

Moore, Darren J. ;

Standaert, David G. ;

Kojima, Kyoko ;

Mobley, James A. ;

West, Andrew B. .

HUMAN MOLECULAR GENETICS, 2013, 22 (24) :4988-5000

← 1 2 3 4 5 6 7 8 9 10 →